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ABSTRACT 
From a regulatory perspective foot-and-mouth disease (FMD) vaccines represent a special case due 
to the number and antigenic diversity of strains that might be used alone or in combination within 
the context of an authorisation. 
New guidelines have been developed proposing that an FMD vaccine should be defined as a 
formulation of ingredients including defined amounts of one or more antigens that vary only in the 
number and types of antigen present. These new guidelines are in line with those previously 
proposed for equine influenza vaccines. Slaughter policies being less and less popular in the 
European Union, there is a tendency to use so-called marker vaccines associated with a 
companion diagnostic test. Such methodology has already been used for vaccination against 
pseudo-rabies and infectious bovine rhinotracheitis. Sub-unit marker vaccines against classical 
swine fever have also been developed; such vaccines are also envisaged against foot-and-mouth 
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The recent epidemic of FMD in the United Kingdom, the current Commission reviews of both 
pharmaceutical and FMD legislation, and a greater perception that future control strategies might 
involve a policy of “vaccination to live” have all contributed to the Committee for Veterinary 
Medicinal Products (CVMP) initiating the preparation of guidelines on the requirements for FMD 
vaccines. 
This paper will describe the approach taken in the draft guideline to those features that make FMD 
vaccines a “special case” in terms of authorisation. 
Whether or not the new proposals are ultimately adopted will depend on the outcome of the 
process of scientific and legal consultation through which the guidelines will now progress. These 
new guidelines are partly influenced by other guidelines previously developed on the 
harmonisation of requirements for equine influenza vaccines, namely specific requirements for 
substitution of a strain or strains. 
Slaughter policies being unpopular in the European Union, so-called marker vaccines associated 
with companion diagnostic tests have been developed which allow the differentiation of infected 
from vaccinated animals. Such vaccines are already used to protect pigs against pseudo-rabies and 
cattle against infectious bovine rhinotracheitis. 
Sub-unit marker vaccines are already available for vaccinating pigs against classical swine fever 
and similar approaches could be developed to produce marker vaccines against FMD. 
Foot-and-Mouth Disease Vaccines – Regulatory Aspects 
In regulatory terms, FMD vaccines are often seen by their manufacturers, and to some extent by 
their users, as a ‘special case’ due to the special nature of the disease against which they provide 
protection. From a legal and regulatory perspective, however, FMD vaccines, like all vaccines, are 
immunological veterinary medicinal products and are therefore subject to the requirements of the 
veterinary pharmaceutical Directive 2001/82/EC. This directive requires that all veterinary 
medicines that are placed on the market within the European Union must be authorised by means 
of a marketing authorisation and lays down the minimum requirements in terms of quality, safety 
and efficacy that medicines must meet to obtain an authorisation. The directive provides an 
exemption from the requirement for an authorisation when a product is to be used in the event of 
‘serious disease epidemic’ provided there is no authorised medicine for use against the disease 
concerned and provided the European Commission is informed of the detailed conditions of use. 
The term ‘serious disease epidemic’ is not further defined but clearly applies to outbreaks of FMD. 
The European Commission itself utilises this exemption to allow use without an authorisation of 
vaccines prepared using antigens maintained in the strategic antigen reserves of the EU FMD 
Antigen Bank. 
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New guidelines for FMD vaccines have been prepared by an ad hoc group of the Committee for 
Veterinary Medicinal Products of the European Medicines Evaluation Agency based in London. 
The CVMP ad hoc group comprises members of (i) the Immunological Working Party of the CVMP, 
(ii) the Research Group of the European Commission for the Control of FMD of the FAO, and (iii) the 
OIE. Invited as observers are representatives from DG Enterprise and DG SANCO of the European 
Commission and from the European manufacturers of FMD vaccines. The group has met on several 
occasions and is currently finalising the first draft of the ‘Guideline on requirements for vaccines 
against foot-and-mouth disease’ which will go out for consultation during 2002. Like all CVMP 
guidelines, the document is intended to provide guidance for manufacturers seeking to place FMD 
vaccines on the market within the EU. The group has consulted widely with other international 
organisations to ensure that the draft proposals have wide acceptance. Ultimately the standards 
set will be those that will apply in the EU and authorities in other regions will have to consider to 
what extent they may wish to apply them in their own areas. 
Within the EU, directive 2001/82/EC requires that any product placed on the market must meet the 
requirements of the relevant monograph of the European Pharmacopoeia where one exists for the 
type of product concerned. In the case of FMD vaccines, there is a monograph laying down the 
minimum requirements for inactivated FMD vaccines for ruminants. Group 15V of the European 
Pharmacopoeia has published a revision proposal for this monograph and is currently working to 
develop a monograph for FMD vaccines for pigs. The CVMP ad hoc group has taken account of the 
revised proposal in preparing the draft guidelines and has put forward a number of proposed 
amendments to the revised proposal for consideration by Group 15 V. During the consultation 
process on both documents care will be taken to ensure that they remain compatible and 
complementary. 
The Precedent of equine Influenza Vaccines (EMEA) 
Equine influenza has remained among the main acute contagious respiratory diseases of horses 
world-wide. Equine influenza is represented by two subtypes : Influenza A/equine 2 virus (H3N8) 
which is the most important cause of respiratory diseases in the horse, and Influenza A/equine 1 
virus (H7N7) which is still circulating subclinically but is almost considered as extinct. 
However, a divergence in the evolution of A/equine 2 (H3N8) viruses has occurred since 1987 and 
two families of viruses are now circulating. These were designated European-like and American-
like, although representatives of both families had been isolated in both continents [1]. There is 
increasing evidence from field studies that antigenic drift in the gene coding for the 
haemagglutinin (HA), which is the major surface protein of these influenza A strains, eventually 
renders vaccine strains obsolete and is likely to compromise vaccine efficacy [1-3]. 
A formal reporting mechanism on antigenic/genetic drift or shift of equine influenza viruses and a 
vaccine strain selection system has been set up, so that vaccine manufacturers and regulatory 
authorities are informed of the potential need to update vaccine virus strains. 
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An Expert Surveillance Panel, including representatives from three WHO Reference Laboratories 
and from three OIE Reference Laboratories reviews every year the epidemiological and virological 
information and makes recommendations about suitable vaccine strains. These recommendations 
are published annually by the OIE in its Bulletin [4], As antigenic drift in equine influenza occurs at 
a slower rate than in human influenza, it is considered that a regular update of the strains could be 
necessary every three to five years. 
The development of effective vaccines can now be facilitated by the availability of reliable in vitro 
assays such as : 
-Single Radial Diffusion (SRD) to measure vaccine bulk antigen content in terms of HA content 
-Single Radial Haemolysis (SRH) to measure serological responses. 
For in-process controls, SRD provides a reliable method of measuring HA content of equine 
influenza bulk antigens, although it cannot be used on final adjuvanted products. Use of SRD tests 
is therefore limited to the in-process control of adjuvanted vaccines. SRD tests can provide a great 
improvement on the Chick Cell Agglutination (CCA) test as it is not susceptible to wide test 
variation and measures immunologically active HA [5], 
SRH is a sensitive and reproducible method for measuring antibody to HA. 
A new outbreak associated with a possible breakdown of existing vaccines may require a change in 
the formulation of such vaccines. It is expected that manufacturers will wish to make such changes 
in response to evidence of antigenic drift and on the need for such a change from the report and 
recommendation from the Expert Surveillance Panel. 
Equine influenza vaccines are well characterised, and it is unlikely that the replacement of one 
strain by another would lead to such substantial changes as to justify a new full set of safety and 
efficacy tests to be carried out. In addition, there is a need to consider reduction of the number of 
animals used in the testing of medicinal products wherever possible. Therefore, provided there 
have been no or few adverse reactions with the previous formulation, a two-fold approach is 
proposed for the testing of the new formation : 
-cross-references to the original dossier would be accepted for those parts which remain 
unchanged ; 
-where necessary, the analytical, safety and efficacy sections of the original dossier would need to 
be amended and new additional data generated. The three expert reports will also require 
updating from those submitted for the previous formulation. 
Marker Vaccines Against Classical Swine Fever 
Large-scale vaccination against classical swine fever using classical, attenuated vaccines, is no 
longer allowed in the European Union ; slaughter policy is the rule. Nevertheless, several countries 
in the Union have to face regular outbreaks mainly due to the existence of a reservoir in wildlife, 
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the wild boar (Sus scrofa) [6]. One solution could be to use marker vaccines. Sub-unit marker 
vaccines have recently been developed by expressing the major immunogen of classical swine 
fever pestivirus (CSFV), protein E2, in a baculovirus expression system [7,8], These subunit vaccines 
would permit vaccinated animals to be distinguished from infected ones by serology. These 
vaccines have been evaluated and accepted by the European Medicinal Evaluation Agency (EMEA). 
The companion diagnostic test is based on the detection of antibodies directed against another 
major immunogen (non-structural protein NS2) not contained in the vaccine. 
Unfortunately, independent experiments showed that the system is yet to be improved. In fact, 
those sub-unit vaccines being inactivated vaccines are not as efficacious as the previous 
attenuated ones [9]. Moreover, the available companion diagnostic tests are not yet reliable and 
therefore impede the practical use of these vaccines. 
Improved marker vaccines could, nevertheless, help to solve the problem of classical swine fever in 
Europe since it seems difficult to control the disease without vaccination [10,11]. 
Towards Foot-and-Mouth Disease Marker Vaccines 
An area of particular interest in the new FMD vaccines guidelines is the incorporation of guidance 
on FMD marker vaccines. These vaccines would be based on the detection of antibodies directed to 
one or more of the non-structural (NS) proteins of the virus. Manufacturers may therefore wish to 
provide potential customers with information on whether or not their vaccine induces antibody to 
NS proteins. Modem FMD vaccines contain purified preparations of virions from which tissue 
culture components, including NS proteins, have been removed to a greater or lesser degree. 
There is currently insufficient information on the immunogenicity of the various NS proteins to set 
levels below which FMD vaccines can be considered to be ‘free’. What is important is the ability of 
any residual, contaminating NS protein to induce an antibody response in the target species that is 
sufficient to interfere with a diagnostic test. The guideline therefore proposes that manufacturers 
should look for antibody to defined NS proteins in the sera of cattle (or other species for which the 
vaccine is indicated) that have been repeatedly immunised with vaccines containing the maximum 
amount and number of FMD antigens permitted under the authorisation. The guideline does not 
attempt to prescribe which antigen(s) should be studied nor which test should be used, but 
requires that the test used is fully validated. The manufacturing process must include a purification 
step to remove NS protein contamination and manufacturers can support their claim by 
demonstrating, using suitable immunochemical methods, that their antigen preparations are free 
from defined NS protein(s) or contain only low levels. There is no EU legislation covering the 
evaluation or authorisation of diagnostic tests. This, together with the fact that ‘vaccinated’ and 
‘infected’ states are not mutually exclusive in FMD means that claims to ‘differentiate’ infection 
from vaccination or for ‘marker’ vaccines are inappropriate and should not be included on the 
summary of product characteristics (SPC) for FMD vaccines authorised in the EU. Claims that 
vaccines do not interfere with the detection of infected animals by means of NS antibody tests 
would be acceptable. There is currently no consensus on which NS protein is the most reliable 
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marker of infection and the tests available have been validated to different levels. The claims made 
in relation to NS proteins must clearly reflect the studies presented and should be limited to 
stating which NS protein has been studied and by which test. In this way, potential customers can 
make informed decisions on an appropriate choice of a vaccine and a companion diagnostic test to 
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